Examining the Future of Molecular Imaging

February 9, 2009 CPDC

HAMILTON: FEBRUARY 9, 2009 – The future of molecular imaging and its impact on patient care highlighted the CPDC’s inaugural probe development workshop on January 30.

More than 120 participants, spanning multiple sectors – academia, health care, not-for-profit, federal/provincial government and industry – gathered at the University Club on McMaster University’s campus in Hamilton, Ontario. Workshop attendees learned about the latest innovations in molecular imaging and associated technologies from leaders in the field.

Featured speakers included:

Jason S. Lewis, PhD, chief of Radiochemistry and associate vice chair of Basic Research at Memorial Hospital for Cancer and Allied Diseases, as well as an associate member within Memorial Sloan-Kettering Cancer Center.
John Joyal, PhD, vice president of Discovery Research at Molecular Insight Pharmaceuticals in Cambridge, MA
Brian Warrington, PhD, former vice president of Technology Development at GlaxoSmithKline in the United Kingdom
Raymond Gibson, PhD, former senior investigator at Merck Research Laboratories in Philadelphia, PA

CPDC Scientific Director and CEO John Valliant presented an overview of the Centre and the scope of services provided. He also opened the CPDC’s inaugural Call for Proposals where applicants from Canadian not-for-profit research institutions with expertise in molecular probe development are eligible for project awards.


For more information, please contact:

T: 905-525-9140, ext 21212
E: info@imagingprobes.ca

More news from CPDC

CPDC’s Radiopharmaceutical Manufacturing Facility Receives Clearance from FDA

Hamilton, Ontario, Canada – January 9, 2020 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that, following a successful U.S. Food and Drug Administration (FDA) inspection in July, CPDC’s site in Hamilton, Ontario, is cleared to ship products to the U.S.  Justyna Kelly, interim

Centre for Probe Development & Commercialization (CPDC) Appoints New Interim CEO

Hamilton, Ontario, December 3, 2019 – Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing as of today that the Company’s Board of Directors has appointed Justyna Kelly as Interim Chief Executive Officer effective immediately. Dr.  Joe McCann will stay on as an Advisor

Study gives Ontario men access to advanced prostate cancer imaging

LONDON, Ontario – Led by researchers at Lawson Health Research Institute, a multi-centre registry trial is testing the use of a new imaging tracer, called a PSMA tracer, for early detection of recurrent prostate cancer. The registry gives patients access to a new type of imaging and will assess the impact on patient care. PSMA

For more information contact us at: